SCHEMBL1668968

SCHEMBL1668968

C=CC(=O)Nc1cccc(C(=O)O)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.65
LTB4R Q15722 1/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
CREBBP Q92793 1/20 0.54
HPSE Q9Y251 1/20 0.54
PARP1 P09874 2/20 0.53
PARP15 Q460N3 2/20 0.53
PARP14 Q460N5 2/20 0.53
PARP10 Q53GL7 2/20 0.53
CBS P35520 1/20 0.53
MITF O75030 1/20 0.51
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
IRAK1 P51617 1/20 0.50
LPAR1 Q92633 1/20 0.50
LPAR2 Q9HBW0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19889016 0.87 TGM2 (0.66) TGM2MEN1KMT2ARAB9ACREBBP
SCHEMBL1925142 0.86 KMT2A (0.71) TGM2MEN1KMT2ANPC1RAB9A
SCHEMBL4103284 0.85 TGM2 (0.76) TGM2LMNALPAR1LPAR2
SCHEMBL8686781 0.85 PARP1 (0.68) TGM2MEN1KMT2APARP1PARP15
SCHEMBL7776267 0.82 TGM2 (0.57) TGM2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL503852 0.82 TGM2 (0.57) TGM2MEN1KMT2ALMNA
SCHEMBL15798246 0.81 CREBBP (0.79) LTB4RMEN1KMT2ANPC1RAB9A
SCHEMBL9364431 0.81 CREBBP (0.79) LTB4RMEN1KMT2ANPC1RAB9A
SCHEMBL9364423 0.81 CREBBP (0.79) LTB4RMEN1KMT2ANPC1RAB9A
SCHEMBL22272087 0.80 CREBBP (0.63) LTB4RMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120059828-A Surface-functionalized two-dimensional nanomaterial with high dispersion stability and preparation method and application thereof 中国科学院兰州化学物理研究所 2025-05-30 CN claimed
CN-121950260-A Dispersing method of nano material in nonpolar solvent, stripping and dispersing method of two-dimensional material 中国科学院兰州化学物理研究所 2026-05-01 CN disclosed
CN-120059828-A Surface-functionalized two-dimensional nanomaterial with high dispersion stability and preparation method and application thereof 中国科学院兰州化学物理研究所 2025-05-30 CN disclosed
WO-2025076470-A1 SOX10 INHIBITORS AND USES THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2025-04-10 WO disclosed
WO-2024175024-A1 NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2024-08-29 WO disclosed
WO-2024125532-A1 NOVEL HETEROCYCLIC COMPOUND ACTING AS CDKS INHIBITOR, AND USE THEREOF 杭州德睿智药科技有限公司 2024-06-20 WO disclosed
WO-2023227125-A1 NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2023-11-30 WO disclosed
EP-3684776-B1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE UNIV NOTTINGHAM (GB) 2023-11-01 EP disclosed
CN-112717196-B Adhesive composition for repairing hard tissue 嘉兴市京吟生物科技有限公司 2022-12-23 CN disclosed
CN-113332486-B Adhesive composition for hard tissue repair and kit for hard tissue repair 嘉兴市京吟生物科技有限公司 2022-09-20 CN disclosed
EP-3129371-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2017-02-15 EP disclosed
WO-2015154022-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-10-08 WO disclosed
WO-2015154022-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-10-08 WO disclosed
US-20120295874-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2012-11-22 US disclosed
US-20120295874-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2012-11-22 US disclosed
US-20120295874-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2012-11-22 US disclosed
EP-2485678-A1 COFERONS AND METHODS OF MAKING AND USING THEM Cornell University (US) 2012-08-15 EP disclosed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 WO disclosed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 WO disclosed
US-5719151-A PHTHALAZINEDIONE COMPOUND; POLYMERASE INHIBITOR SHALL SYDNEY (GB) 1998-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295874-A1 COFERONS AND METHODS OF MAKING AND USING THEM MYOF, FTH1, HCCS TGM2 2876/4885LTB4R 2583/4885MEN1 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.